Clinical Trial Update: Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors [Phase 1]

View source ↗

Summary

This ClinicalTrials.gov update describes a Phase 1 study evaluating MNPR-101-DFO*-89Zr as a diagnostic imaging agent for adults with various solid tumors, curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Colorectal Cancer
• Gastric Cancer
• Lung Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Triple-negative Breast Cancer
• Urothelial Carcinoma

Drugs mentioned

• MNPR-101-DFO*-89Zr

Snippet

Sponsor: Monopar Therapeutics | Conditions: Solid Tumor, Adult, Bladder Cancer | Phase 1 | Status: RECRUITING